Artelo Biosciences, Inc.

NasdaqCM:ARTL Stock Report

Market Cap: US$3.7m

Artelo Biosciences Dividend

Dividend criteria checks 0/6

Artelo Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-16.8%

Buyback Yield

Total Shareholder Yield-16.8%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend updates

No updates

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28
Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Mar 09

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Nov 02
Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Relief For Cancer Patients In Artelo Bioscience Pipeline

Jul 12

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20
Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04
Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ARTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARTL's dividend payments have been increasing.


Dividend Yield vs Market

Artelo Biosciences Dividend Yield vs Market
How does ARTL dividend yield compare to the market?
SegmentDividend Yield
Company (ARTL)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.5%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast (ARTL) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ARTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ARTL's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ARTL has not reported any payouts.


Discover strong dividend paying companies